A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01) — Stella
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
(88 sites) United States
Providence Medical Foundation, Fullerton, California Henry Ford Health System, Detroit, Michigan Baptist Cancer Center, Memphis, Tennessee SCRI Oncology Partners, Nashville, Tennessee John Peter Smith Hospital, Fort Worth, Texas Show all 88 locations Key details Collaborators
Merck Sharp & Dohme LLC
Enrollment target
~510 participants
Primary completion
June 2028
Last updated January 2026